We are a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
Our PCA approach may represent a transformative step in the evolution of regenerative medicine, reducing complexity by temporarily reactivating progenitor cells already located at the tissue target site – and pre-programmed to make specific cell types.
Naturally repairing or reversing damage caused by degenerative disease
Hearing loss caused by damage to the sensory cells of the ear impacts hundreds of millions of people globally. Currently there are no FDA-approved treatments to address the underlying condition.
Institute Professor, Massachusetts Institute of Technology
Harvard Medical School; Brigham & Women's Hospital
Harvard Medical School; Broad Institute of MIT & Harvard
Harvard Medical School; Center for Systems Biology at MGH.
Scripps Research Center
Harvard Medical School; Boston Children’s Hospital
Dana-Farber Cancer Institute
Harvard Medical School; Brigham & Women’s Hospital
PureTech Health; Former President of R&D, Pfizer
UT Southwestern; Howard Hughes Medical Institute
Columbia University
Harvard University; Joslin Diabetes Center
Wellcome Trust-MRC Cambridge Stem Cell Institute; MS Society Cambridge Centre for Myelin Repair
Gladstone Institute of Cardiovascular Disease; University of California San Francisco
